Dissecting Phenotype Switching in Early Stage Melanomas
剖析早期黑色素瘤的表型转换
基本信息
- 批准号:10676721
- 负责人:
- 金额:$ 61.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-04 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAllelesAnimalsAntitumor ResponseAutologousB-LymphocytesBasic ScienceBehaviorBiologicalBiological MarkersBiological ModelsBiologyCD34 geneCD8-Positive T-LymphocytesCD8B1 geneCell CommunicationCell LineageCellsClinicalClinical DataData SetDermalDevelopmentDiagnosisDifferentiation AntigensDiseaseDisease OutcomeDisease ProgressionEpigenetic ProcessEtiologyExhibitsExperimental ModelsFailureFetal LiverFutureGene Expression ProfileGenesGenetic TranscriptionGenetically Engineered MouseGenomeGoalsGrowthHLA-A geneHematopoietic stem cellsHost Defense MechanismHumanImmuneImmune responseImmune signalingImmune systemImmunohistochemistryImmunological ModelsImplantIn VitroInnate Immune ResponseInterferonsInvadedMacrophageMalignant - descriptorMalignant NeoplasmsMelanoma CellModelingMolecularMusMutationNatural Killer CellsNeoplasm MetastasisOrganPathway interactionsPatientsPhasePhenotypePrevention strategyPrognosisProteinsRadialReproducibilityResearchRoleSTING agonistsSignal PathwaySignal TransductionSkinStimulator of Interferon GenesSystemTechniquesTestingThickThymic TissueTimeTissue SampleUltraviolet B RadiationValidationWorkadvanced systemantagonistanti-CD20anti-tumor immune responseclinical practicecohortdraining lymph nodegenetic signaturehuman datahuman modelhuman tissuehumanized mouseimmune cell infiltrateimmunoregulationin vivoin vivo Modelinnovationirradiationmalignant statemelanocytemelanomamouse modelneoplastic cellnovelpathogenpotential biomarkerpredictive markerpreventprognosticprognostic assaysprognosticationreconstitutionsurvival predictiontranscriptometumortumor growthtumor progressiontumor-immune system interactionsultraviolet
项目摘要
Project Summary
Melanoma continues to be a devastating cancer. Early stage melanomas represent the majority of melanomas
that are diagnosed and managed in the US. It is becoming clearer that metastatic dissemination and seeding
occurs very early during tumor progression while the tumor is still localized to the skin without signs of other
organ involvement. To effectively battle with this disease we must understand the molecular underpinnings of
biologically early tumors, in particular host defense mechanisms against the tumor cells. Basic research in
early melanomas has not made significant progress over the past decades mostly due to lack of murine
systems that model early disease. Genetically engineered murine models of melanoma represent many
shortcomings, and at best they mimic late aggressive tumors (murine genome) within the mice immune
system. In this proposal, we will mimic early malignant states in novel in vivo humanized murine models that
we have developed, in which highly immune deficient mice are reconstituted with human CD34+ hematopoietic
stem cells and challenged with HLA-A allele-matched human melanoma cells. By ultraviolet (UVB/A)
irradiation, we will induce additional mutations as in human skin, and study the progression of tumors as they
grow in time and space. Our preliminary studies indicate that a transcriptional switch occurs within the
tumor cells, it accompanies unique host immune responses, and this crosstalk dictates the fate of the
tumor towards progression or elimination. Stimulator of interferon – STING – signaling gets activated once
melanoma cells acquire an aggressive phenotype suggesting a role during tumor progression. Here, we
propose to establish paradigm-shifts in the concept of non-aggressive melanomas transitioning into an
aggressive phenotype that will directly impact clinical practice. We will investigate: 1) changes within the tumor
(mutations, pathways) that co-occur within the immune microenvironment (cell lineages, signals) during early
disease progression using humanized mouse models (Aim1), 2) pro- or anti-tumor responses in the presence
or absence of STING activation in early disease leveraging the humanized mouse and 3D skin models (Aim 1),
3) reversal of phenotypes and testing causality by modulating immune cell subpopulations (Aim 2), and 4)
development and validation of a prognostic assay applied to early melanomas that predicts survival (Aim 3).
Successful completion of this project promises to bring new model systems to the melanoma (and cancer) field
that enable studying human tumor and human immune system interactions. If offers a major leap in early stage
melanoma research, and deepens our understanding by revealing new tumor cell intrinsic or extrinsic
mechanisms of disease progression.
项目摘要
黑色素瘤仍然是一种毁灭性的癌症。早期黑色素瘤占黑色素瘤的大多数。
在美国进行诊断和管理。越来越清楚的是,转移性传播和播种
在肿瘤进展过程中发生非常早,而肿瘤仍然局限于皮肤,没有其他迹象。
器官参与。为了有效地与这种疾病作斗争,我们必须了解
生物学早期肿瘤,特别是宿主对肿瘤细胞的防御机制。基础研究
在过去的几十年里,早期黑色素瘤没有取得重大进展,主要是由于缺乏鼠
模拟早期疾病的系统。黑色素瘤的基因工程小鼠模型代表了许多
缺点,最好的情况下,它们模拟小鼠免疫内的晚期侵袭性肿瘤(鼠基因组)。
系统在这个提议中,我们将在新的体内人源化鼠模型中模拟早期恶性状态,
我们已经开发了,其中高度免疫缺陷的小鼠用人CD 34+造血重建,
干细胞并用HLA-A等位基因匹配的人黑素瘤细胞攻击。紫外线(UVB/A)
辐射,我们将诱导额外的突变,在人类皮肤,并研究肿瘤的进展,因为他们
在时间和空间中成长。我们的初步研究表明,转录开关发生在
肿瘤细胞,它伴随着独特的宿主免疫反应,这种串扰决定了肿瘤细胞的命运。
肿瘤进展或消除。干扰素刺激物- STING -信号传导一旦被激活
黑色素瘤细胞获得侵袭性表型,表明其在肿瘤进展中的作用。这里我们
建议在非侵袭性黑色素瘤转变为恶性黑色素瘤的概念中建立范式转变,
侵袭性表型将直接影响临床实践。我们将研究:1)肿瘤内的变化
(突变,途径),共同发生在免疫微环境(细胞谱系,信号)在早期
使用人源化小鼠模型的疾病进展(Aim 1),2)在存在下的促肿瘤或抗肿瘤应答
或在利用人源化小鼠和3D皮肤模型的早期疾病中不存在STING激活(Aim 1),
3)通过调节免疫细胞亚群逆转表型和测试因果关系(目的2),和4)
开发和验证应用于早期黑色素瘤的预测存活率的预后测定法(Aim 3)。
该项目的成功完成有望为黑色素瘤(和癌症)领域带来新的模型系统
能够研究人类肿瘤和人类免疫系统的相互作用。如果在早期阶段提供了一个重大飞跃
黑色素瘤研究,并通过揭示新的肿瘤细胞内在或外在加深我们的理解
疾病进展的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julide T. Celebi其他文献
Julide T. Celebi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julide T. Celebi', 18)}}的其他基金
The Oncogene Activated Mitochondrial Unfolded Protein Response Regulates Senescence Biology
癌基因激活线粒体未折叠蛋白反应调节衰老生物学
- 批准号:
10598922 - 财政年份:2023
- 资助金额:
$ 61.29万 - 项目类别:
Dissecting Phenotype Switching in Early Stage Melanomas
剖析早期黑色素瘤的表型转换
- 批准号:
10358965 - 财政年份:2022
- 资助金额:
$ 61.29万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 61.29万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 61.29万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 61.29万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 61.29万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 61.29万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 61.29万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 61.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 61.29万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 61.29万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 61.29万 - 项目类别: